Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Analysis of Liquidity Ratios

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Johnson & Johnson, liquidity ratios

Microsoft Excel
Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Current ratio
Quick ratio
Cash ratio

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The liquidity position of the company exhibits a generally declining trend across the observed period. All three liquidity ratios – current, quick, and cash – demonstrate decreases from 2021 to 2025, suggesting a reduced ability to meet short-term obligations using readily available assets.

Current Ratio
The current ratio decreased from 1.35 in 2021 to 1.03 in 2025. While remaining above 1.0 for the entire period, indicating a positive ability to cover current liabilities with current assets, the decline suggests a weakening short-term solvency. The most significant decrease occurred between 2021 and 2022, followed by a more gradual decline in subsequent years.
Quick Ratio
The quick ratio, which excludes inventory from current assets, shows a more pronounced decline, moving from 1.04 in 2021 to 0.69 in 2025. This indicates a diminishing capacity to meet short-term liabilities with the most liquid assets. The ratio fell below 1.0 in 2022 and continued to decrease throughout the period, signaling increasing reliance on inventory to cover current obligations.
Cash Ratio
The cash ratio, representing the ability to cover current liabilities with only cash and cash equivalents, experienced the steepest decline, decreasing from 0.70 in 2021 to 0.37 in 2025. This suggests a substantial reduction in the company’s most liquid assets relative to its current liabilities. The ratio consistently decreased year-over-year, highlighting a growing dependence on other current assets to meet immediate obligations.

Collectively, these trends suggest a consistent erosion of the company’s liquidity over the five-year period. While the current ratio remains above 1.0, the declines in the quick and cash ratios indicate a growing vulnerability to short-term financial pressures. Further investigation into the underlying drivers of these declines, such as changes in working capital management or debt levels, would be warranted.


Current Ratio

Johnson & Johnson, current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Current Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The current ratio exhibited fluctuating performance over the five-year period. Initially, the ratio decreased before stabilizing and then showing a slight downward trend.

Current Ratio Trend
The current ratio began at 1.35 in 2021. A substantial decrease was observed in 2022, falling to 0.99. The ratio then recovered to 1.16 in 2023, indicating improved short-term liquidity. A modest decline to 1.11 occurred in 2024, followed by a further decrease to 1.03 in 2025. This represents the lowest value within the observed period.

The movement in the current ratio appears to be influenced by the relative changes in current assets and current liabilities. While current assets experienced a decrease from 2021 to 2023, they showed a slight increase in the subsequent two years. Current liabilities, however, consistently increased throughout the entire period, potentially contributing to the observed downward pressure on the current ratio.

Asset and Liability Dynamics
Current assets decreased from US$60,979 million in 2021 to US$53,495 million in 2023, before increasing to US$55,893 million in 2024 and US$55,624 million in 2025. Current liabilities increased steadily from US$45,226 million in 2021 to US$54,126 million in 2025.

The declining current ratio in the later years suggests a potential weakening in the company’s ability to meet its short-term obligations using its current assets. Continued monitoring of this trend, alongside analysis of the underlying components of current assets and liabilities, is recommended.


Quick Ratio

Johnson & Johnson, quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Marketable securities
Accounts receivable trade, less allowances
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Quick Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The quick ratio exhibited a declining trend over the five-year period. Initially at 1.04 in 2021, the ratio decreased to 0.69 by 2025. This indicates a weakening ability to meet short-term obligations with highly liquid assets.

Overall Trend
A consistent downward trajectory is apparent in the quick ratio. The most significant decrease occurred between 2021 and 2022, dropping from 1.04 to 0.71. Subsequent years show continued, albeit less dramatic, declines.
Quick Ratio Components
Total quick assets experienced a decrease from US$46,891 million in 2021 to US$37,280 million in 2025. While there were minor fluctuations, the overall trend is negative. Current liabilities, conversely, generally increased over the same period, rising from US$45,226 million to US$54,126 million. This divergence between decreasing quick assets and increasing current liabilities is the primary driver of the declining quick ratio.
Year-over-Year Changes
The largest year-over-year decrease in the quick ratio was observed from 2021 to 2022, a reduction of 0.33. From 2022 to 2023, the ratio improved slightly to 0.82, but then resumed its decline, reaching 0.78 in 2024 and 0.69 in 2025. The decrease from 2024 to 2025 was 0.09.

The observed trend suggests a potential increase in liquidity risk over time. While a quick ratio below 1.0 does not automatically indicate financial distress, the consistent decline warrants further investigation into the composition of current assets and liabilities, and the underlying reasons for these changes.


Cash Ratio

Johnson & Johnson, cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Marketable securities
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Cash Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio exhibited a declining trend over the five-year period. Initially, the ratio stood at 0.70 in 2021, indicating a relatively strong ability to meet current obligations with solely cash and cash equivalents. However, subsequent years witnessed a decrease in this metric.

Cash Ratio Trend
The cash ratio decreased from 0.70 in 2021 to 0.42 in 2022, representing a substantial decline. A partial recovery was observed in 2023, with the ratio increasing to 0.50. This improvement was not sustained, as the ratio edged down to 0.49 in 2024 and further decreased to 0.37 in 2025, marking the lowest point in the observed period.

Total cash assets experienced a decrease from US$31,608 million in 2021 to US$23,519 million in 2022, contributing to the initial drop in the cash ratio. While cash assets saw a modest increase in 2024, reaching US$24,522 million, this was insufficient to offset the concurrent rise in current liabilities. The cash position further declined to US$20,102 million by 2025.

Current Liabilities Impact
Current liabilities increased significantly from US$45,226 million in 2021 to US$55,802 million in 2022, exacerbating the decline in the cash ratio. Although current liabilities decreased to US$46,282 million in 2023, they subsequently increased again, reaching US$54,126 million in 2025. This consistent upward pressure on current liabilities, coupled with fluctuations in cash assets, has negatively impacted the company’s cash ratio.

The observed trend suggests a weakening ability to cover immediate liabilities with available cash. The ratio’s decline from 2021 to 2025 indicates a growing reliance on other current assets or financing options to meet short-term obligations.